Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.
A pancreatic cancer expert on why Revolution Medicines’ study could ‘open up a new era’ of treatment
Revolution Medicines announced a stunning survival benefit for its experimental drug in a Phase 3 pancreatic cancer study ...
Discover how Anneo Biotech is quietly leading India's probiotic revolution, building the future of preventive healthcare.
In what looks to be the largest follow-on stock offering in biopharma history, US oncology company Revolution Medicines ...
Revolution Medicines (RVMD) shares soared on April 13 after the biotech firm said its pancreatic cancer drug, daraxonrasib, ...
What if the biggest winners in biotech weren’t the ones promising miracle cures, but the ones quietly supplying the picks and ...
ARLINGTON, Mass., March 11, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) announces that it is ready to ship its first commercial AI product in approximately 14 days, transforming the Company ...
CRISPR-Cas9 technology has revolutionized biotechnology by providing an efficient, precise, and versatile tool for genome editing. This RNA-guided system allows scientists to target specific DNA ...
Agricultural biotechnology, or “agri-biotech,” uses science to make plants better. Think of it like giving crops special ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results